Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Momenta Pharma (MNTA)

Momenta Pharma (MNTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,320,700
  • Shares Outstanding, K 98,707
  • Annual Sales, $ 75,590 K
  • Annual Income, $ -176,060 K
  • 60-Month Beta 2.03
  • Price/Sales 17.39
  • Price/Cash Flow N/A
  • Price/Book 4.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.50
  • Number of Estimates 3
  • High Estimate -0.48
  • Low Estimate -0.52
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.91 +12.34%
on 08/23/19
14.48 -7.60%
on 09/17/19
+0.94 (+7.56%)
since 08/20/19
3-Month
9.51 +40.69%
on 07/22/19
14.48 -7.60%
on 09/17/19
+0.68 (+5.35%)
since 06/20/19
52-Week
9.51 +40.69%
on 07/22/19
28.15 -52.47%
on 09/21/18
-14.42 (-51.87%)
since 09/20/18

Most Recent Stories

More News
Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the appointment...

MNTA : 13.38 (+0.45%)
Momenta Pharmace Shares Up 18.1% Since SmarTrend's Buy Recommendation (MNTA)

SmarTrend identified an Uptrend for Momenta Pharmace (NASDAQ:MNTA) on July 31st, 2019 at $11.41. In approximately 2 months, Momenta Pharmace has returned 18.05% as of today's recent price of $13.47.

MNTA : 13.38 (+0.45%)
Momenta (MNTA) Up 10% Since Last Earnings Report: Can It Continue?

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MNTA : 13.38 (+0.45%)
Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss

Momenta (MNTA) reports a wider loss and misses on sales in Q2 .

MYL : 21.00 (unch)
MNTA : 13.38 (+0.45%)
ABBV : 72.39 (+1.00%)
REGN : 295.87 (+3.40%)
Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Misses Revenue Estimates

Momenta (MNTA) delivered earnings and revenue surprises of -176.19% and -43.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

MNTA : 13.38 (+0.45%)
Momenta: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Friday reported a loss of $114 million in its second quarter.

MNTA : 13.38 (+0.45%)
Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results

-- Launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), the Company's third study of its FcRn inhibitor; top-line data expected by end of 2021 --

MNTA : 13.38 (+0.45%)
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, announced the launch of an...

MNTA : 13.38 (+0.45%)
Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that the...

MNTA : 13.38 (+0.45%)
Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MNTA : 13.38 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade MNTA with:

Business Summary

Momenta Pharmaceuticals is a leader in the analysis, characterization and design of complex pharmaceutical products. Their scientific foundation is a set of tools and methods that allow them to develop a deep understanding of the links between a compound's chemical structure, biological function and...

See More

Key Turning Points

2nd Resistance Point 13.87
1st Resistance Point 13.63
Last Price 13.38
1st Support Level 13.17
2nd Support Level 12.96

See More

52-Week High 28.15
Fibonacci 61.8% 21.03
Fibonacci 50% 18.83
Fibonacci 38.2% 16.63
Last Price 13.38
52-Week Low 9.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar